Paradigm expects to use the funding to expand its platform and scale its partnerships with health systems and life sciences companies. The design of the platform will aim to reduce operational burdens on physicians and healthcare provider organizations while improving access for patients, the company said in a Jan. 25 press release.
“Today the system is broken in almost every respect—patient access is too narrow, incentives are mis-aligned, and poor trial design slows development,” Robert Nelson, co-chair of Paradigm’s board and co-founder and managing director of Arch Venture, said in the release. “We saw an opportunity to fundamentally rebuild the system and fix the business model.”
Kent Thoelke was named Paradigm’s chief executive. Previously, Thoelke was chief innovation officer at Icon and the chief scientific officer at PRA Health Sciences.
Additionally, Paradigm announced the acquisition for an undisclosed price of Deep Lens, a clinical trial patient recruitment provider in oncology.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.